Sign in →

Order Code QUAD1 Quad Screen (Second Trimester) Maternal, Serum


Necessary Information


In order to provide the best results, either answer the order entry questions or provide the required information using the Second Trimester Maternal Screening Alpha-Fetoprotein / Quad Screen Patient Information (T595).



Specimen Required


Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Collection Instructions:

1. Do not collect specimen after amniocentesis as this could affect results.

2. Centrifuge and aliquot serum into plastic vial within 2 hours of collection

Additional Information:

1. For an assessment that includes neural tube defect results, gestational age must be between 15 weeks, 0 days and 22 weeks, 6 days.

2. Assessments for trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome) only are available between 14 weeks, 0 days and 22 weeks, 6 days.

3. Initial or repeat testing is determined in the laboratory at the time of report and will be reported accordingly. To be considered a repeat test for the patient, the testing must be within the same pregnancy and trimester, with interpretable results for the same tests, and both tests are performed at Mayo Clinic.

4. Maternal Serum Screening patient education brochure (T522) is available upon request.


Useful For

Prenatal screening for open neural tube defect (alpha-fetoprotein only), trisomy 21 (alpha-fetoprotein, human chorionic gonadotropin, estriol, and inhibin A) and trisomy 18 (alpha-fetoprotein, human chorionic gonadotropin, and estriol)

Method Name

Immunoenzymatic Assay

Reporting Name

QUAD SCRN (2nd Tri) Maternal, S

Specimen Type

Serum

Specimen Minimum Volume

0.75 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Serum Refrigerated (preferred) 7 days
  Frozen  90 days
  Ambient  7 days

Reject Due To

Gross hemolysis Reject
Gross lipemia OK
Gross icterus OK

Reference Values

NEURAL TUBE DEFECTS:

An alpha-fetoprotein (AFP) multiple of the median (MoM) <2.5 is reported as screen negative.

AFP MoM ≥2.5 (singleton and twin pregnancies) are reported as screen positive.

 

DOWN SYNDROME:

Calculated screen risks <1/270 are reported as screen negative, risks ≥1/270 are reported as screen positive.

 

TRISOMY 18:

Calculated screen risks <1/100 are reported as screen negative, risks ≥1/100 are reported as screen positive.

 

An interpretive report will be provided.

Method Description

This 4-marker screen includes alpha-fetoprotein (AFP), estriol (uE3), human chorionic gonadotropin (total beta-hCG: ThCG), and inhibin A. Analyte values are compared to median values at a given gestational age and multiple of the median (MoM) results obtained. The MoM results are used in a multivariate algorithm that includes the mother's age to derive risk factors for trisomy 21 (Down syndrome) and trisomy 18 (Edwards syndrome). The screen for neural tube defects (NTD) uses the AFP MoM only. An interpretive report will be provided. The Beckman Access AFP, ThCG, uE3, and inhibin A assays are automated immunoenzymatic assays with paramagnetic separation and chemiluminescent detection.(Package insert: Beckman Coulter Access AFP, Total bhCG, Unconjugated Estriol, and Inhibin A. Beckman Coulter; 2019)

Day(s) Performed

Monday through Friday

Performing Laboratory

Mayo Clinic Laboratories in Rochester

CPT Code Information

81511